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Distinguishing Hypertension From Hypertrophic Cardiomyopathy as a
Cause of Left Ventricular Hypertrophy
In most hypertensive patients, left ventricular (LV) wall
thickness is normal or only mildly increased (≤13 mm).1
A minority of patients may have more substantial
hypertrophy (up to 16 mm) and fall into a “gray zone”
in which electrocardiographic and echocardiographic
features are indistinguishable from those of hypertro-
phic cardiomyopathy (HCM).1–4 Clinical evaluation
after appropriate antihypertensive treatment may help
define the correct diagnosis.
A 51-year-old man was referred to our center after an
incidental finding of high blood pressure (220/120 mm
Hg). At first clinical presentation, the patient was
asymptomatic and took no drugs. Physical examination
showed a loud second heart sound and no murmurs.
FIGURE 1. Electrocardiogram in December 2011 (A). Electrocardiogram in March 2012 (B).
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His blood pressure was 190/115 mm Hg. Findings from
electrocardiography exhibited signs of LV hypertrophy
(LVH) (RV5+SV1 = 56 mm), ST-segment abnormali-
ties, and negative T waves in anterolateral leads
(Figure 1A). Echocardiography showed marked sym-
metric LVH (septal thickness, 18 mm; posterior wall
thickness, 16 mm; LV mass/height2.7, 73 g/m2.7),5 nor-
mal LV cavity (LV diastolic diameter/body surface area,
FIGURE 2. Echocardiography in December 2011 (A). Echocardiography in March 2012 (B). Parasternal long-axis (leftward) and short-axis
(rightward) view at end diastole. Maximum end-diastolic thickness of the anterior wall decreased from 18 mm to 14 mm in 3 months. Dist
indicates distance.
FIGURE 3. Magnetic resonance imaging (MRI) in November 2013. On the left, cine MRI using balanced steady state free precession technique
(short axis) shows normal left ventricular wall thickness at end diastole. On the right, contrast-enhanced inversion recovery imaging (short axis)
shows the absence of myocardial enhancement.
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2.7 cm/m2), mildly enlarged left atrium (LA volume/
body surface area, 30 mL/m2), and normal ejection
fraction (62%). Aortic root was mildly dilated. Dia-
stolic filling showed impaired relaxation (Figure 2A).
The patient had no family history of HCM or sudden
death.
LVH was likely to be secondary to hypertension, but
overlapping hypertension on HCM could not be
excluded. We prescribed an antihypertensive treatment
with ramipril 10 mg and amlodipine 10 mg, but blood
pressure was not adequately controlled. Two weeks
later, we substituted valsartan/hydrochlorothiazide 320/
12.5 mg for ramipril 10 mg.6 b-Blockers were not
prescribed because of bradycardia. Secondary causes
of hypertension were excluded.
The patient was reevaluated after 3 months. Blood
pressure was 110/70 mm Hg. Findings from electrocar-
diography were strikingly different: voltages did not
meet anymore Sokolow-Lyon criterion for LVH
(RV5+SV1 = 29 mm), ST-segment abnormalities had
normalized, and anterolateral negative T waves had
reverted to positive (Figure 1B). Findings from echocar-
diography showed significant reduction in LV wall
thickness (septum, 14 mm; posterior wall, 10 mm; LV
mass/height2.7, 48 g/m2.7) (Figure 2B). Three months
later, amlodipine was discontinued. After 2 years of
optimal blood pressure control with valsartan and
hydrochlorothiazide, the patient underwent magnetic
resonance imaging (MRI). The left ventricle had normal
wall thickness (maximum 11 mm), cavity dimension
(end-diastolic LV volume index, 71 mL/m2), and ejec-
tion fraction (68%). LV mass/height2.7 was 30 g/m2.7.
Post-contrast images revealed no delayed enhancement
(Figure 3).
MAKING THE CORRECT DIAGNOSIS
The finding of severe LVH in hypertensive patients may
sometimes create a clinical dilemma: Is a coexistent
cardiomyopathy present? Or is LVH a secondary
consequence of severe chronic hypertension? A defini-
tive diagnosis may be difficult to resolve.
It is quite uncommon to find severe LVH in a
hypertensive 50-year-old patient. Diagnostic difficulties
generally arise in elderly patients and, in the past, led to
the definition of a distinct entity termed hypertensive
hypertrophic cardiomyopathy of the elderly, character-
ized by severe concentric cardiac hypertrophy (wall
thickness ≥16 mm; septal:posterior wall-thickness ratio,
1:1), small LV cavity, supernormal indexes of systolic
function, impaired diastolic function, and enlarged left
atrium.7
At first clinical presentation, the clinical and mor-
phological features of our patient were compatible with
the diagnosis of overlapping hypertension on HCM.
Three-month treatment with antihypertensive drugs,
though, was sufficient to reverse LVH. LVH in patients
with HCM is caused by mutations in sarcomere genes
and is not reversible. Conversely, LVH in hypertensive
patients is secondary to increased afterload and may
regress during antihypertensive treatment. Angiotensin
receptor blockers seem to be particularly effective for
this purpose.6 Regression of LVH in our patient led us
to exclude HCM and lean toward the diagnosis of LVH
secondary to hypertension. The absence of delayed
gadolinium enhancement on MRI supported the latter
diagnosis.8
CONCLUSIONS
A minority of hypertensive patients fall into the mor-
phological gray zone between secondary LVH and
HCM. Regression of LVH after antihypertensive treat-
ment reveals hypertension as the underlying cause of
LVH, excluding HCM.
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